[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354106-105":59,"doc-detail-354106-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","saicar-drives-t-regulatory-cell-differentiation-and-foxp3-maintenance-to-promote-immunotherapy-resistance","SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance","","Regulatory T (Treg) cells in the tumor microenvironment suppress PD-1 immune checkpoint blockade, and metabolic reprogramming is a key driver of antitumor immunity. The study identifies SAICAR, a purine biosynthesis intermediate, as a metabolic driver of Treg induction and resistance to anti–PD-1 therapy. SAICAR binds PPM1A, inhibits SMAD3 dephosphorylation, sustains TGFβ–SMAD3 signaling, boosts FOXP3 transcription, and stabilizes the Treg lineage. Elevated intratumoral SAICAR correlates with increased Treg accumulation, impaired effector T cells, and PD-1 blockade failure, while SAICAR reduction and low-dose 6-mercaptopurine restore immunity and synergize without systemic toxicity. Findings support SAICAR as a therapeutically actionable immunometabolic regulator linking purine metabolism to immune evasion.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/saicar-drives-t-regulatory-cell-differentiation-and-foxp3-maintenance-to-promote-immunotherapy-resistance/354106/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/saicar-drives-t-regulatory-cell-differentiation-and-foxp3-maintenance-to-promote-immunotherapy-resistance/354106.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why do regulatory T (Treg) cells undermine PD-1 checkpoint blockade?","Question",{"text":113,"@type":114},"Treg cells within the tumor microenvironment suppress antitumor immune responses, weakening the effectiveness of PD-1 immune checkpoint blockade.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does SAICAR promote Treg induction and immunotherapy resistance?",{"text":118,"@type":114},"SAICAR binds PPM1A to inhibit SMAD3 dephosphorylation, sustaining TGFβ–SMAD3 signaling that enhances FOXP3 transcription and stabilizes the Treg lineage.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the therapeutic implication of reducing SAICAR?",{"text":122,"@type":114},"Genetic or pharmacologic reduction of SAICAR restores antitumor immunity and sensitizes tumors to PD-1 therapy, and low-dose 6-mercaptopurine disrupts SAICAR-driven immunosuppression with synergy to anti–PD-1 treatment.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354106,1790315908,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":14,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","SAICAR Drives T Regulatory Cell Differentiation and  \nFOXP3 Maintenance to Promote Immunotherapy Resistance  \nMao Li1,2, Yaqi Chen1,3, Anyi Liu1,2,3, Qi Wu1,2, Changsheng Huang1, Da Song1, Fuqing Hu1, Jingqin Lan1,2, Chen Huang4, Junbo Hu1,2, and Guihua Wang1,2,5  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Regulatory T (Treg) cells within the tumor microenvironment critically undermine the efficacy of PD-1 immune checkpoint blockade. Metabolic reprogramming has emerged as a critical determinant of antitumor immunity, highlighting the need to define the metabolic cues that program Treg differentiation in cancer. In this study, we identified the purine biosynthesis intermediate succinylaminoimidazole carboxamide ribose-50-phosphate (SAICAR) as a key metabolic driver of Treg induction and resistance to anti–PD-1 immunotherapy. Mechanistically, SAICAR directly bound to the serine/threonine phosphatase PPM1A, inhibiting SMAD3 dephosphorylation and thereby sustaining TGFβ–SMAD3 signaling. Persistent SMAD3 activation enhanced FOXP3 transcription and stabilized the Treg lineage. In both human tumors and mouse models, elevated intratumoral SAICAR levels were associated with increased Treg accumulation, suppression of effector T-cell function, and failure of PD-1\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | blockade. Genetic or pharmacologic reduction of SAICAR restored antitumor immunity and sensitized tumors to PD-1 therapy. Notably, low-dose 6-mercaptopurine disrupted SAICAR-driven immunosuppression and synergized with anti– PD-1 treatment without inducing systemic immune toxicity. Together, these findings establish SAICAR as an immunometabolic regulator that links purine metabolism to immune evasion and highlight a therapeutically actionable pathway to overcome metabolite-driven resistance to immune checkpoint blockade.\u003Cbr>Significance: SAICAR is necessary and sufficient to drive Treg-mediated immunosuppression in the tumor microenvironment, linking tumor metabolism and immunosuppression and providing mechanistic insights for metabolism-guided combination immunotherapy. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nCancer immunotherapy has transformed the therapeutic landscape of oncology by harnessing the immune system to eliminate malignant cells. Immune checkpoint inhibitors, particularly antibodies targeting PD-1 or its ligand PD-L1, have achieved durable clinical responses across multiple malignancies, including melanoma, non–small cell lung cancer, gastric cancer, and colorectal cancer (1–6) . Resistance to immune checkpoint blockade  \n1GI Cancer Research Institute, Tongji Hospital, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, China. 2Hubei Provincial Key Laboratory of Cancer Neuroscience, Wuhan, China. 3Department of Thyroid and Breast Surgery, Tongji","cbCaie5TdNCK77iY","https://ap.wps.com/l/cbCaie5TdNCK77iY","pdf",9696836,"English","# Introduction\n## Cancer immunotherapy and immune checkpoint blockade\n## Resistance mechanisms linked to the tumor microenvironment\n## Metabolic reprogramming and immunometabolism","[{\"question\":\"Why do regulatory T (Treg) cells undermine PD-1 checkpoint blockade?\",\"answer\":\"Treg cells within the tumor microenvironment suppress antitumor immune responses, weakening the effectiveness of PD-1 immune checkpoint blockade.\"},{\"question\":\"How does SAICAR promote Treg induction and immunotherapy resistance?\",\"answer\":\"SAICAR binds PPM1A to inhibit SMAD3 dephosphorylation, sustaining TGFβ–SMAD3 signaling that enhances FOXP3 transcription and stabilizes the Treg lineage.\"},{\"question\":\"What is the therapeutic implication of reducing SAICAR?\",\"answer\":\"Genetic or pharmacologic reduction of SAICAR restores antitumor immunity and sensitizes tumors to PD-1 therapy, and low-dose 6-mercaptopurine disrupts SAICAR-driven immunosuppression with synergy to anti–PD-1 treatment.\"}]","SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance | PDF",1790108991,48,[147,151],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/ac3b1d84ec3576a892bf6429c5e94104.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/2c32acc7396145cd816e017a9ca18400.webp",982,1314]